Ogeda

CompanyBelgium

Ogeda develops one asset, approved (fezolinetant in hot flashes). Mostly small molecule acting on TACR3; based in Belgium.

1
Asset
Furthest stage
Approved
1
Trial
2
Signals

Pipeline

1
  • fezolinetant

    Blocks neurokinin 3 receptors to reduce menopausal hot flashes.

    Approved, Small molecule, TACR3, hot flashes, menopause

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials1
  • Signals2
  • Similar companies6

Intelligence